(1:09) Melissa Piliang, MD, of Cleveland Clinic, discusses comorbid chronic kidney disease in patients with psoriasis and psoriatic arthritis. (1:42) ...
Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...
Germany: A team of researchers from Germany developed a deep learning model using a convolutional neural network (CNN) to ...
Zacks Investment Research on MSN20d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis StudyProtagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra (JNJ-2113), an investigational targeted oral peptide that ...
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...
It encompasses all indications approved for the STELARA ® reference product, including psoriasis (PsO), psoriatic arthritis (PsA), Crohn's disease (CD), ulcerative colitis (UC) in adults ...
Most common (≥ 2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections. Most common (≥ 2% ...
STEQEYMA is available in both subcutaneous injection and intravenous infusion and is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and pediatric ...
Recent research captures more evidence on the psoriasis–type 2 diabetes link and attempts to pinpoint the possible genetic and pathophysiologic mechanisms underlying this connection. This study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback